Safety and Immunogenicity Study of MenC-TT Vaccine (NeisVac-C) in Toddlers Previously Immunized With PCV7 (Prevenar®) [clinicaltrials:NCT00617760]

Bio2RDF uri

Safety and Immunogenicity Study of MenC-TT Vaccine (NeisVac-C) in Toddlers Previously Immunized With PCV7 (Prevenar®) [clinicaltrials:NCT00617760]

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

http://bio2rdf.org/clinicaltrials:NCT00617760

Bio2RDF identifier

NCT00617760

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00617760

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT00617760

actual enrollment [clinicaltrials_vocabulary:actual-enrollment]

330

http://www.w3.org/2001/XMLSchema#integer

arm group [clinicaltrials_vocabulary:arm-group]

NCT00617760 arm group c4ca4238a0b923820dcc509a6f75849b [clinicaltrials_resource:NCT00617760/arm-group/c4ca4238a0b923820dcc509a6f75849b]

NCT00617760 arm group c81e728d9d4c2f636f067f89cc14862c [clinicaltrials_resource:NCT00617760/arm-group/c81e728d9d4c2f636f067f89cc14862c]

NCT00617760 arm group eccbc87e4b5ce2fe28308fd9f2a7baf3 [clinicaltrials_resource:NCT00617760/arm-group/eccbc87e4b5ce2fe28308fd9f2a7baf3]

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:e478999f19782873e6063cf7552726b8

brief summary [clinicaltrials_vocabulary:brief-summary]

The purpose of this stu ...... ion of MenC-TT vaccine alone.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Safety and Immunogenicity Stud ...... mmunized With PCV7 (Prevenar®)

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Number of subjects achieving PCV7-specific (elicited by each vaccine pneumococcal serotype) antibody concentrations of at least 0.2 mg/mL 1 month after a booster vaccination with PCV7 1 month after booster vaccination with PCV7 [clinicaltrials_resource:366510c6eb3091fb7225b3bbe0a1ed8e]

completion date [clinicaltrials_vocabulary:completion-date]

2009-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00617760 [clinicaltrials_resource:53481435d0815b989871eeac5307da21]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2008-02-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

Group C Meningococcal Polysaccharide-Tetansu Toxoid Conjugate (MenC-TT) [clinicaltrials_resource:10f55897c07182bf3c4e0c0335a5a77a]

7-valent Pneumococcal CRM197-conjugate vaccine (PCV7) [clinicaltrials_resource:648fa333fe93529a76ad9ff9cdc48ffc]

Group C Meningococcal Polysaccharide-Tetansu Toxoid Conjugate (MenC-TT) vaccine and 7-valent Pneumococcal CRM197-conjugate vaccine (PCV7) [clinicaltrials_resource:e58a5b3c625c0939ea972c6400076570]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2015-05-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Pfizer [clinicaltrials_resource:c1b9f1c2d5cc1361ccf28b0108bd7179]

location [clinicaltrials_vocabulary:location]

Werderstrasse 3 [clinicaltrials_resource:6e9bd4e9f899461027b5a0adc1d4f030]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00617760

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

Open-label, Randomized, 3-arm, ...... nized During Infancy With PCV7

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

670,701

http://www.w3.org/2001/XMLSchema#integer

overall status [clinicaltrials_vocabulary:overall-status]

Completed [clinicaltrials_resource:07ca5050e697392c9ed47e6453f1453f]

oversight [clinicaltrials_vocabulary:oversight]

Germany: Paul-Ehrlich-Institut [clinicaltrials_resource:1e7c9bcda51397542ecb8e452545f186]

phase [clinicaltrials_vocabulary:phase]

Phase 3 [clinicaltrials_resource:8357418e2694434468870b487644532d]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2009-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:dbd41868ee618d3e64daa1adf8c3a8a0]

source [clinicaltrials_vocabulary:source]

Pfizer [clinicaltrials_resource:c1b9f1c2d5cc1361ccf28b0108bd7179]

start date [clinicaltrials_vocabulary:start-date]

2008-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00617760 study design [clinicaltrials_resource:28ea7716bb16482480122ee7397ab97c]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00617760

verification date [clinicaltrials_vocabulary:verification-date]

2015-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00617760

http://www.w3.org/2001/XMLSchema#string

title

Safety and Immunogenicity Stud ...... mmunized With PCV7 (Prevenar®)

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

Safety and Immunogenicity Stud ...... ) [clinicaltrials:NCT00617760]

@en